NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that Company management will make two presentations at the 2nd Baltic Stem Cell Meeting, running from Friday, May 31 to Sunday, June 2, 2013, and that the conference will feature a session with multiple researchers from around the world discussing advances using very small embryonic-like stem cells (VSELs(TM) Technology).

The conference focuses on innovative applications of stem cells in multiple areas, the clinical application of umbilical cord blood in regenerative medicine, news and updates on VSEL(TM) Technology, stem cell mobilization and homing, novel directions in hematopoietic transplants, stem cells and cancer, stem cells and aging, and more. Dr. Robin L. Smith, Chairman and CEO of NeoStem, will chair a panel and give a talk titled "From the bench to the clinic: Considerations in cell therapy development." Dr. Denis O. Rodgerson, Director of Stem Cell Science of NeoStem, will speak on "Generation of skeletal structures by human very small embryonic-like (VSEL) stem cells."

The conference will also feature some of the researchers from the United States, Europe and Asia who have expanded on the initial studies of VSEL(TM) Technology carried out by Dr. Mariusz Ratajczak, including:

"The research being presented by these scientists both enhances our understanding of the potential of VSELs as the ultimate cell for regenerative therapy and provides further validation of the capabilities of these cells," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We are happy to see research into VSEL(TM) Technology by a growing number of scientists who are not affiliated with NeoStem and we welcome the interest of the scientific community in these extraordinary cells."

NeoStem is pursuing a development program relating to its VSEL(TM) Technology in selected clinical applications and markets based on unmet medical need, target patient population size, regulatory strategy, and overall commercial market. Through both grant funding and NeoStem's own funding, the Company is exploring the potential of VSEL(TM) Technology in the treatment of periodontitis, healing complex skin and soft tissue wounds, corneal regeneration and repair, age-related macular degeneration, nerve regeneration and acute radiation syndrome in a parallel but staggered timeline. NeoStem anticipates that a single clinical manufacturing process will be developed for these indications, collectively, and that the major pacing item will be the generation of preclinical data to support the filing of an investigational new drug application (IND) for a Phase 1 clinical trial, the first of which it expects to be in periodontitis.

The event takes place at the Radisson SAS Hotel, Szczecin, Poland and is organized by Pomeranian Medical University.

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

For more information, please visit: http://www.neostem.com.

About VSEL(TM) Technology

Read the original here:
NeoStem Announces Presentations at 2nd Baltic Stem Cell Meeting and Session to Feature VSEL(TM) Technology